Comparison of Covid-19 Vaccines Under Different Coverage Levels and Delivery Periods

Ongoing COVID-19 pandemic has caused many hospitalizations, deaths, and huge economic cost worldwide for approximately one and half years. Vaccination has been the most important intervention strategy to stop infectious diseases as COVID-19. Several COVID-19 vaccines have been developed, produced, and delivered to people in several countries. These vaccines have different efficacy levels in between the first and second doses as well as after the second dose and durations to reach the maximum efficacy levels. In this study, we compared three COVID-19 vaccines, Moderna, Biontech, and Sinovac in terms of the number of infected and death people by considering their efficacy levels and durations to reach the maximum efficacy levels on SIR (Susceptible-Infected-Recovered) network model. Since it is a great problem to access enough vaccines for people worldwide, we also consider different coverage levels and delivery periods in the model. The proposed SIR network model is calibrated according to actual COVID-19 cases of six countries. Results show that Biontech is the best vaccine to decrease overall cases; however, results of Moderna and Biontech are quite close and differences between results are not statistically significant in some scenarios. Sinovac vaccines do not perform well compared to Moderna and Biontech. Moderna and Biontech vaccines reduce the number of cases by %24 compared to 17% for Sinovac under 10% coverage level whereas they reduce the number of cases by 70% compared to 58% for Sinovac under 50% coverage level.

Keywords:

COVID-19, SIR Network Model, Vaccination Simulation,

PDF

___

BBC, https://www.bbc.com/turkce/haberler-turkiye-56267795, Access Date: April 18, 2021.
Calvó-Armengol, Antoni, and Matthew O. Jackson (2007). Networks in Labour Markets: Wage and Employment Dynamics and Inequality. Journal of Economic Theory, 132(1): 27–46. https://doi.org/10.1016/j.jet.2005.07.007
Chaney, T. (2014). The Network Structure of International Trade. American Economic Review, 104(11): 3600–3634. https://doi.org/10.1257/aer.104.11.3600
Couch, R. B. (1999). Measures for control of influenza. Pharmacoeconomics, 16(1), 41-45. https://doi.org/10.2165/00019053-199916001-00006
COVID-19 Vaccine Tracker, Coronavirus pandemic disease, https://covid19.trackvaccines.org/, Access Date: April 18, 2021.
Craig, B. R., Phelan, T., Siedlarek, J. P., & Steinberg, J. (2020). Improving Epidemic Modelling with Networks. Economic Commentary, (2020-23). https://doi.org/10.26509/frbc-ec-202023
Demirbilek, M. (2020). YAYsim: Salgın Modelleme ve Karar Destek Sistemi. Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi, 7 (1), 104-112. https://doi.org/10.35193/bseufbd.675734
Demirbilek, M. (2021). The Effect of School/Workplace Closures on COVID-19 Related Incidents. Avrupa Bilim ve Teknoloji Dergisi, (23), 62-69. https://doi.org/10.31590/ejosat.842793
Elliott, Matthew, Benjamin Golub, and Matthew O. Jackson (2014). Financial Networks and Contagion. American Economic Review, 104(10): 3115–3153. https://doi.org/10.1257/aer.104.10.3115
KFF, https://www.kff.org/coronavirus-covid-19/issue-brief/what-does-a-multi-dose-series-mean-for-the-covid-19-vaccination-effort/, Access Date: April 18, 2021.
MCBU, https://www.mcbu.edu.tr/Haber/MCBUTipFakultesiHastanesiSaglikCalisanlarininYuruttugu_SARSCoV2InaktifSinovacCoronavacAsisininBagisiklikYaniti_ArastirmasiSonuclandi_09_20_7, Access Date: April 30, 2021.
Our World in Data, https://ourworldindata.org/covid-vaccinations?country=~TUR/, Access Date: April 18, 2021.
T.C. Sağlık Bakanlığı Covid-19 Aşısı Bilgilendirme Platformu, https://covid19asi.saglik.gov.tr/, Access Date: April 18, 2021.
The Lancet Infectious Diseases (2018). How to be ready for the next influenza pandemic. Lancet Infect. Dis., vol. 18, no. 7, p. 697. https://doi.org/10.1016/S1473-3099(18)30364-5
Worldometer Data Statistics, Coronavirus pandemic disease, https://www.worldometers.info/coronavirus/#countries, Access Date: April 18, 2021.